Dyslipidemia Formulary

Question 1

brand name: atorvatstatin

Answer 1

Lipitor

Question 2

dosing: atorvastatin

Answer 2

Moderate: 10-20 mg daily
High: 40-80 mg daily

Question 3

adverse effects: statins

Answer 3

• muscle symptoms
• fatigue

Question 4

monitoring: statins

Answer 4

FLP
- baseline
- 4-12 weeks following statin initiation
- every 3-12 months as clinically indicated

Consider also:
- baseline CK in individuals with increased risk of adverse muscle effectss
- CK while on statin therapy in individuals with muscle symptoms
- hepatic function in individuals with s/sxs of hepatotoxicity

Question 5

brand name: rosuvastatin

Answer 5

Crestor

Question 6

dosing: rosuvastatin

Answer 6

moderate: 5-10 mg
high: 20-40 mg

Question 7

brand name: simvastatin

Answer 7

zocor

Question 8

dosing: simvastatin

Answer 8

low: 10 mg
moderate: 20-40 mg

Question 9

brand name: pravastin

Answer 9

Pravachol

Question 10

dosing: pravastatin

Answer 10

low: 10-20 mg
moderate: 40-80 mg

Question 11

brand name: lovastatin

Answer 11

Altoprev, Mevacor

Question 12

dosing: lovastatin

Answer 12

low: 20 mg
moderate: 40-80 mg

Question 13

brand name: pitastatin

Answer 13

Livalo

Question 14

dosing: pitastatin

Answer 14

Moderate: 1-4 mg

Question 15

brand name: fluvastatin

Answer 15

Lescol

Question 16

dosing: fluvastatin

Answer 16

low: 20-40 mg
moderate: fluvastatin 40 mg BID or fluvastatin XL 80 mg

Question 17

brand name: ezetimibe

Answer 17

Zetia

Question 18

dosing: ezetimibe

Answer 18

10 mg daily

Question 19

adverse effects: ezetimibe

Answer 19

• fatigue
• diarrhea
• GI upset

Question 20

monitoring parameters: ezetimibe

Answer 20

FLP
- 4 to 12 weeks after starting therapy
- rechecked 3 to 12 months therafter

Hepatic Transanimase levels
- baseline FLTs

Question 21

brand name: evolucumab

Answer 21

Repatha

Question 22

dosing: evolucumab

Answer 22

• 140 mg once every 12 weeks
• 420 mg once montly

Question 23

adverse effects: PCSK9 monoclonal antibodies

Answer 23

• GI upset
• increased LFTs
• injection site pain
• myalgia
• influenza

Question 24

monitoring parameters: PCSK9 monoclonal antibodies

Answer 24

FLP
- Lipid profile (fasting or nonfasting) before initiating treatment
- FLP checked 4-12 weeks after starting therapy
- 3 to 12 months thereafter

• signs and symptoms of allergic reaction

Question 25

brand name: alirocumab

Answer 25

Praluent

Question 26

dosing: alirocumab

Answer 26

HFH: 150 mg subq once every 2 weeks

hyperlipidemia: initial 75 mg once every 2 weeks or 300 mg once every 4 weeks. max 150 mg every 2 weeks

Question 27

brand name: cholestyramine

Answer 27

Questran, Prevalite

Question 28

dosing: cholestyramine

Answer 28

• initial 4 g 1 to 2 times/day
• maximum 24 g/day
• maintenance: 8 to 16 g/day/2 doses

Question 29

adverse effects: bile acid resins

Answer 29

• constipation
• bloating
• nausea
• flatulence
• impaired absorption of fat-soluble vitamins (A,D,E,K)
• hypernatremia
• hypercholeremia
• GI obstruction

Question 30

monitoring parameters: bile acid resins

Answer 30

FLP
- Lipid profile (fasting or nonfasting) before initiating treatment
- FLP checked 4-12 weeks after starting therapy
- 3 to 12 months thereafter

Question 31

brand name: colsevelam

Answer 31

WelChol

Question 32

dosing: colesevelam

Answer 32

3.75 g/day in 1 to 2 divided doses

Question 33

monitoring parameters: colesevelam

Answer 33

HbA1c twice yearly in patients who have stable glycemic control and are meeting treatment goals or quarterly in patients in whom treatment goals have not been met

Question 34

brand name: colestipol

Answer 34

Colestid